Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
IGF-1 LR3 vs Somapacitan (Sogroya)
An educational, source-based comparison of IGF-1 LR3 and Somapacitan (Sogroya) — how each peptide works, what it's researched for, and what to know before going deeper.
A modified form of insulin-like growth factor-1 with an Arg3 substitution and N-terminal extension that reduces binding to IGFBPs, dramatically extending its half-life and free fraction in circulation.
- Muscle protein synthesis (preclinical)
- Tissue repair signaling
- Cell-culture growth applications
- • Hypoglycemia risk via insulin-receptor cross-activity.
- • Not FDA-approved for human therapeutic use; banned by WADA.
Once-weekly growth hormone analog for adults and children with GHD.
GH analog with a non-covalent albumin-binding side chain that extends half-life, enabling once-weekly subcutaneous administration with sustained IGF-1 elevation.
- Adult growth hormone deficiency
- Pediatric GH deficiency
- • FDA-approved.
- • Monitor glucose; injection-site reactions possible.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| IGF-1 LR3 | Long-R3-IGF-I pharmacology and IGFBP interactions | Journal of Endocrinology | 2001 | Characterized extended half-life and bioactivity vs native IGF-1. |
| Somapacitan (Sogroya) | REAL trials | JCEM | 2020 | Comparable body composition and IGF-1 response to daily somatropin. |
Side-effect & safety grid
- Hypoglycemia risk via insulin-receptor cross-activity.
- Not FDA-approved for human therapeutic use; banned by WADA.
- FDA-approved.
- Monitor glucose; injection-site reactions possible.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
IGF-1 LR3 vs Somapacitan (Sogroya) — Key differences
- Class: IGF-1 LR3 is classified as Growth Factor, while Somapacitan (Sogroya) is GH Analog · Endocrine.
- Primary research focus: IGF-1 LR3 — muscle protein synthesis (preclinical); Somapacitan (Sogroya) — adult growth hormone deficiency.
- Tag: Growth · Recovery vs FDA-Approved · Endocrine.